64.3 Longitudinal Tobacco Cessation Pharmacotherapy

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

64.3 Longitudinal Tobacco Cessation Pharmacotherapy

Key Takeaways Explain This Topic AI

Cigarette smoking is the single leading preventable cause of disease, disability, and death in the United States; brief clinical intervention utilizing the 5 A's (Ask, Advise, Assess, Assist, Arrange) significantly increases long-term quit rates.

First-line pharmacotherapy combined with behavioral counseling yields 6-month abstinence rates of 25–35%, compared to only 3–5% with unassisted 'cold turkey' cessation attempts.

Varenicline (alpha-4-beta-2 nicotinic receptor partial agonist) is the most effective single pharmacologic agent for smoking cessation; the landmark EAGLES trial definitively established its neuropsychiatric safety across psychiatric and non-psychiatric cohorts.

Combination Nicotine Replacement Therapy (transdermal patch for continuous 24-hour background delivery PLUS a short-acting PRN formulation for acute cravings) achieves clinical efficacy equivalent to varenicline and is vastly superior to single-agent NRT monotherapy.

Bupropion SR (150 mg BID) is an effective oral non-nicotine option that mitigates post-cessation weight gain, but is strictly contraindicated in patients with a history of seizure disorders, anorexia nervosa, or bulimia nervosa.

Last updated: September 2026

Epidemiology, Health Burden & Timeline of Cessation Benefits

Tobacco use remains the single leading preventable cause of premature death, disability, and disease in the United States, accounting for over 480,000 deaths each year (approximately 1 in every 5 deaths). Smoking drives catastrophic morbidity across three major clinical domains: cardiovascular disease (atherosclerosis, myocardial infarction, stroke, peripheral artery disease), chronic pulmonary disease (COPD, emphysema, refractory asthma exacerbations), and oncologic malignancies (causing > 85 % >85\% > 85% of all lung cancers, as well as cancers of the larynx, bladder, kidney, pancreas, esophagus, and cervix).

The Clinical Timeline of Health Recovery After Cessation

Cessation delivers profound, measurable physiological benefits across immediate and long-term timeframes:

20 Minutes : Heart rate and blood pressure decline toward baseline.

12 Hours : Blood carbon monoxide levels drop to normal, restoring arterial oxygen-carrying capacity.

2 Weeks to 3 Months : Circulation improves, lung function ( F E V 1 FEV_1 FE V 1 ​ ) increases by up to 10%, and acute myocardial infarction risk begins to fall.

1 to 9 Months : Coughing and shortness of breath decrease; bronchial ciliary function recovers, dramatically clearing pulmonary secretions and reducing respiratory infection risk.

1 Year : Excess risk of coronary heart disease drops by 50% compared to that of a continuing smoker.

5 Years : Stroke risk drops to that of a non-smoker (5 to 15 years post-cessation).

10 Years : Lung cancer mortality rate is approximately half that of a continuing smoker; risk of mouth, throat, esophagus, bladder, cervix, and pancreas cancer declines substantially.

15 Years : Risk of coronary heart disease equals that of a lifetime non-smoker.

Brief Clinical Behavioral Counseling: The 5 A's & The 5 R's

The USPSTF assigns a Grade A recommendation to screening all adults for tobacco use, advising all tobacco users to quit, and providing behavioral interventions and FDA-approved pharmacotherapy to all non-pregnant adults who smoke. THE 5 A'S FRAMEWORK FOR PATIENTS READY TO QUIT

Step Clinical Action Practical Clinical Application & Phrasing

═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════

• 1. ASK Screen at every encounter "Do you currently use any form of tobacco, cigarettes,
• or electronic vaping devices?"
• ───────────────────────────────────────────────────────────────────────────────────────────────────────────
• 2. ADVISE Clear, strong, personalized advice "Quitting smoking is the single most important step you can
• to quit delivered with empathy take to protect your heart and help manage your COPD."
• ───────────────────────────────────────────────────────────────────────────────────────────────────────────
• 3. ASSESS Determine willingness to make a quit "Are you willing to make a quit attempt within the next
• attempt in the next 30 days 30 days?"
• ───────────────────────────────────────────────────────────────────────────────────────────────────────────

4. ASSIST Provide behavioral counseling plus • Set a firm QUIT DATE (within 2 to 4 weeks).

first-line pharmacotherapy • Prescribe Varenicline or Combination NRT.

• Identify personal triggers and social supports.

• Connect to state quitlines (1-800-QUIT-NOW).

• ───────────────────────────────────────────────────────────────────────────────────────────────────────────
• 5. ARRANGE Schedule structured follow-up Schedule in-person or telephone follow-up contact within
• contact to ensure accountability 1 to 2 WEEKS after the quit date to monitor adherence,

manage drug side effects, and prevent relapse.

═══════════════════════════════════════════════════════════════════════════════════════════════════════════════

The 5 R's Framework for Patients Unwilling to Quit

For patients ambivalent or not currently ready to make a quit attempt within the next 30 days, clinicians should deploy Motivational Interviewing (MI) using the 5 R's framework to build internal motivation:

Relevance : Encourage the patient to identify why quitting is personally relevant (e.g., their children's asthma, personal finances, athletic performance).

Risks : Ask the patient to identify acute risks (shortness of breath, exacerbations), chronic risks (heart disease, cancer), and environmental risks (secondhand smoke harm to household members).

Rewards : Prompt the patient to identify tangible benefits of quitting (food tasting better, saving thousands of dollars annually, improved stamina, home/car smelling clean).

Roadblocks : Help the patient identify barriers to quitting (fear of withdrawal, weight gain, stress, living with another smoker) and brainstorm practical mitigation strategies.

Repetition : Re-evaluate readiness and repeat the motivational intervention at every subsequent clinical encounter without badgering or alienating the patient.

Evidence-Based First-Line Pharmacotherapies

Unassisted "cold turkey" quit attempts carry a dismal long-term success rate of only 3% to 5% at 6 to 12 months. Combining structured behavioral counseling with first-line pharmacotherapy increases 6-month abstinence rates to 25% to 35% . Three first-line pharmacotherapeutic classes are approved by the FDA: COMPARATIVE SUMMARY OF FIRST-LINE CESSATION PHARMACOTHERAPIES

Therapy Mechanism of Action Dosing & Administration Key Clinical Pearls & Risks

═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════════

• Varenicline α4β2 nicotinic acetylcholine • Days 1–3: 0.5 mg daily MOST EFFECTIVE SINGLE AGENT;
• (Chantix) receptor (nAChR) partial • Days 4–7: 0.5 mg BID superior to Bupropion & single NRT;
• agonist; provides dual action • Day 8–Wk 12: 1 mg BID take with full glass of water & food;

(agonist + antagonist) (continue to 24 wks if needed) EAGLES trial: SAFE in psychiatric disease.

• ───────────────────────────────────────────────────────────────────────────────────────────────────────────
• Combination NRT Long-acting patch (steady • Patch: 21 mg/day (if ≥ 10 cig) EQUIVALENT EFFICACY TO VARENICLINE;

(Patch + PRN Gum / basal level) PLUS short-acting or 14 mg/day (if < 10 cig) vastly superior to single-agent NRT;

Lozenge / Inhaler) agent (PRN breakthrough bolus) • Gum/Lozenge: 4 mg (if 1st cig "Chew and park" technique for gum;

≤ 30 min) or 2 mg (> 30 min) PRN avoid acidic drinks 15 min prior.

• ───────────────────────────────────────────────────────────────────────────────────────────────────────────
• Bupropion SR Norepinephrine-dopamine • Days 1–3: 150 mg daily Non-nicotine oral tablet;
• (Zyban / reuptake inhibitor (NDRI); • Day 4–Wk 12: 150 mg BID PREVENTS POST-CESSATION WEIGHT GAIN;
• Wellbutrin SR) weak nAChR antagonist (taken ≥ 8 hours apart) CONTRAINDICATED IN SEIZURES, BULIMIA,

ANOREXIA NERVOSA; safe in CAD.

═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════

1. Varenicline (Chantix)

Mechanism of Action : Varenicline is a synthetic small molecule that acts as a selective partial agonist at α 4 β 2 \alpha_4\beta_2 α 4 ​ β 2 ​ neuronal nicotinic acetylcholine receptors (nAChRs) in the ventral tegmental area (VTA):

Partial Agonism : It produces approximately 30% to 60% of the maximal dopamine release stimulated by nicotine. This basal dopamine release satisfies the mesolimbic reward center, mitigating intense cravings and suppressing acute withdrawal symptoms.

Competitive Antagonism : Because varenicline binds the α 4 β 2 \alpha_4\beta_2 α 4 ​ β 2 ​ receptor with higher affinity than nicotine, if the patient lapses and smokes a combustible cigarette, varenicline competitively prevents inhaled nicotine from binding the receptor. This blocks the surges of dopamine, blunting the reward, satisfaction, and positive reinforcement of smoking.

Efficacy : Multiple network meta-analyses and Cochrane reviews demonstrate that varenicline is the most effective single agent for tobacco cessation, achieving superior 6-month continuous abstinence rates compared to bupropion monotherapy (Odds Ratio [OR] ≈ 1.6 \approx 1.6 ≈ 1.6 ) and single-agent NRT monotherapy (OR ≈ 1.7 \approx 1.7 ≈ 1.7 ).

Dosing & Titration Protocol :

Start medication 1 to 2 weeks prior to the target quit date (allows drug levels to reach steady state before cessation):

Days 1 to 3 : 0.5 mg orally once daily in the morning.

Days 4 to 7 : 0.5 mg orally twice daily (morning and evening).

Day 8 through Week 12 : 1.0 mg orally twice daily.

Maintenance : If the patient achieves complete abstinence at 12 weeks, continue varenicline for an additional 12 weeks (total 24-week course) to consolidate abstinence and prevent late relapse.

Adverse Effects & Administration Pearls :

Nausea : The most frequent side effect (occurring in up to 30% of patients). It is generally mild-to-moderate and diminishes over time. Clinical Pearl : Instruct patients to take varenicline immediately after a meal with a full 8-ounce glass of water to significantly reduce nausea.

Neuropsychiatric & Sleep Symptoms : Vivid, abnormal, or bizarre dreams and insomnia are common. Administering the second daily dose at dinner rather than right before bedtime helps mitigate sleep disturbances.

The EAGLES Landmark Trial & Removal of Black Box Warning :

In 2009, post-marketing reports prompted the FDA to mandate a black box warning regarding potential neuropsychiatric events (depression, suicidal ideation, agitation).

The landmark EAGLES trial (Evaluating Adverse Events in a Global Smoking Cessation Study; > 8 , 000 >8,000 > 8 , 000 participants, including > 4 , 000 >4,000 > 4 , 000 with clinically stable psychiatric disorders) definitively demonstrated no significant difference in neuropsychiatric adverse events between varenicline, bupropion, transdermal nicotine patch, and placebo. In 2016, the FDA removed the black box warning. Varenicline is safe and effective in smokers with stable depression, anxiety, or schizophrenia.

2. Combination Nicotine Replacement Therapy (Combination NRT)

The Flaw of NRT Monotherapy : Single-agent NRT (such as using a nicotine patch alone or nicotine gum alone) has modest efficacy (OR ≈ 1.6 − 1.8 \approx 1.6-1.8 ≈ 1.6 − 1.8 vs. placebo) because:

A transdermal patch delivers slow, steady, 24-hour background nicotine levels but cannot provide rapid bolus spikes to extinguish sudden, intense situational cravings.

Short-acting oral agents (gum, lozenges) provide acute bolus relief but fail to maintain steady basal nicotine levels, leading to frequent subacute withdrawal dips throughout the day.

The Combination Regimen : Combining a long-acting transdermal patch (providing steady 24-hour basal nicotine levels) with a short-acting PRN formulation (gum, lozenge, oral inhaler, or nasal spray for acute breakthrough cravings) achieves clinical efficacy equivalent to varenicline and is vastly superior to single-agent NRT.

Transdermal Nicotine Patch Dosing :

If patient smokes ≥ 10 \ge 10 ≥ 10 cigarettes/day (half a pack or more):

Step 1 : 21 mg/24 hours transdermal patch for 4 to 6 weeks.

Step 2 : 14 mg/24 hours patch for 2 weeks.

Step 3 : 7 mg/24 hours patch for 2 weeks.

If patient smokes < 10 < 10 < 10 cigarettes/day :

Start at Step 2 : 14 mg/24 hours patch for 6 weeks.

Step 3 : 7 mg/24 hours patch for 2 weeks.

Application Pearls : Apply to clean, dry, non-hairy skin on the upper trunk or outer arm daily upon waking. Rotate sites daily to prevent contact dermatitis. If patient experiences vivid dreams or nocturnal insomnia, instruct them to remove the patch at bedtime (16-hour daily wear).

Short-Acting Breakthrough Formulations :

Nicotine Gum & Lozenge :

Dosing is based on the "Time to First Cigarette" (TTFC) upon waking (the best single measure of biological nicotine dependence):

First cigarette ≤ 30 minutes \le 30\text{ minutes} ≤ 30 minutes after waking: Use the 4 mg strength .

First cigarette > 30 minutes > 30\text{ minutes} > 30 minutes after waking: Use the 2 mg strength .

Dosing Schedule : 1 piece every 1 to 2 hours PRN for cravings (minimum 9 pieces/day for the first 6 weeks; maximum 20 to 24 pieces/day).

The "Chew and Park" Technique for Nicotine Gum :

Patients must be explicitly counseled that nicotine gum is NOT chewed like regular confectionery bubblegum .

Instructions : Chew the gum slowly until a peppery taste or slight tingling sensation is felt in the mouth. Immediately "park" the gum between the cheek and buccal gum mucosa . When the tingling subsides (after ~1 minute), chew again until tingling returns, then park in a different location. Repeat over 30 minutes, then discard.

Rationale : Chewing continuously causes the patient to swallow nicotine with saliva, which causes severe dyspepsia, throat burning, hiccups, and nausea , while stomach acid and hepatic first-pass metabolism inactivate over 80% of the swallowed drug. Nicotine must be absorbed trans-mucosally through the oral buccal mucosa.

Avoid Acidic Beverages :

Acidic beverages (coffee, sodas, citrus juices, wine, beer) dramatically lower salivary pH, converting nicotine into its ionized, charged form, which cannot permeate the lipid-rich buccal mucosa .

Clinical Rule : Avoid drinking or eating anything (except plain water) for at least 15 minutes before and during the use of nicotine gum or lozenges.

Nicotine Oral Inhaler : Delivers 4 mg of nicotine vapor into the oral cavity (buccal absorption) via a mouthpiece. Highly satisfying for smokers who miss the behavioral "hand-to-mouth" ritual.

Nicotine Nasal Spray : Rapidly delivers nicotine across the nasal mucosa, achieving the fastest peak serum levels of any NRT (reaches brain within 5–10 minutes). Causes initial nasal burning, sneezing, and lacrimation; high compliance barrier.

3. Bupropion Sustained-Release (Zyban, Wellbutrin SR)

Mechanism of Action : Bupropion is a monocyclic aminoketone that acts as a norepinephrine-dopamine reuptake inhibitor (NDRI) and non-competitive antagonist at neuronal nicotinic receptors. By inhibiting the reuptake of dopamine and norepinephrine in the mesolimbic system and locus coeruleus, bupropion mimics the neurochemical actions of nicotine, blunting withdrawal symptoms and reducing craving.

Key Clinical Niche : Bupropion is particularly advantageous for smokers who express intense concern about post-cessation weight gain . It significantly attenuates weight gain during active therapy (though weight gain often catches up once the drug is discontinued). It is also an ideal dual-purpose agent for patients with comorbid mild-to-moderate major depressive disorder .

Dosing Protocol :

Start medication 1 to 2 weeks before the target quit date :

Days 1 to 3 : 150 mg orally once daily in the morning.

Day 4 through Week 12 : 150 mg orally twice daily.

Administration Rule : Doses must be taken at least 8 hours apart , and the second dose should be taken in the late afternoon (before 5 PM) to minimize insomnia.

STRICT CONTRAINDICATIONS & SAFETY WARNINGS :

History of Seizure Disorder : Bupropion lowers the epileptic seizure threshold in a dose-dependent manner (seizure incidence is ≈ 0.1 % \approx 0.1\% ≈ 0.1% at doses ≤ 300 mg/day \le 300\text{ mg/day} ≤ 300 mg/day ).

Current or Prior Diagnosis of Anorexia Nervosa or Bulimia Nervosa : Patients with eating disorders taking bupropion exhibit a substantially elevated incidence of generalized tonic-clonic seizures due to electrolyte shifts and intrinsic susceptibility.

Abrupt Discontinuation of Alcohol, Benzodiazepines, or Other Sedatives : Further lowers the seizure threshold.

Concurrent Use of Monoamine Oxidase Inhibitors (MAOIs) : Requires a mandatory 14-day washout period.

Cardiovascular Safety : Unlike nicotine, bupropion does not elevate blood pressure or heart rate significantly and is entirely safe in patients with stable coronary artery disease and heart failure.

• Special Clinical Populations & E-Cigarettes
• 1. Pregnant Smokers

Smoking during pregnancy causes severe maternal and fetal morbidity: spontaneous abortion, intrauterine growth restriction (IUGR), low birth weight ( < 2500 g <2500\text{ g} < 2500 g ), placenta previa, placental abruption, premature rupture of membranes, preterm birth, and Sudden Infant Death Syndrome (SIDS) .

First-Line Intervention : Intensive behavioral counseling is the first-line and preferred intervention throughout pregnancy.

Pharmacotherapy Decisions : If behavioral counseling fails and the patient continues to smoke heavily, clinicians may engage in shared decision-making regarding NRT .

Intermittent short-acting formulations (nicotine gum or lozenges) are preferred over 24-hour continuous patches to minimize overall fetal nicotine exposure.

If a patch is required, instruct the patient to remove it at bedtime (16-hour wear).

Varenicline and bupropion are generally avoided as initial agents due to limited human safety data in pregnancy.

2. Electronic Cigarettes (E-Cigarettes / Vaping)

USPSTF Recommendation : The USPSTF concludes that the current evidence is INSUFFICIENT to assess the balance of benefits and harms of electronic nicotine delivery systems (ENDS / e-cigarettes) for tobacco cessation in adults .

Clinical Hazards & The "Dual-Use" Pitfall :

Aerosols from e-cigarettes contain nicotine, ultrafine toxic particles, volatile organic compounds (formaldehyde, acrolein), diacetyl (associated with bronchiolitis obliterans / "popcorn lung"), and heavy metals (nickel, tin, lead).

EVALI (E-cigarette or Vaping Product Use-Associated Lung Injury) : Outbreak characterized by acute respiratory failure, bilateral pulmonary infiltrates, and severe hypoxemia, strongly linked to vitamin E acetate used as a thickening agent in unregulated or illicit vaping cartridges.

The Dual-Use Trap : Many adults who attempt to quit smoking by vaping become "dual users"—smoking combustible cigarettes while also vaping. Dual users experience no reduction in cardiovascular morbidity or mortality and maintain high nicotine dependence.

Youth Addiction Crisis : E-cigarettes have fueled a nationwide epidemic of nicotine addiction among adolescents and young adults, acting as a gateway to combustible tobacco use.

Clinical Recommendation : Primary care clinicians should advise patients against using e-cigarettes for smoking cessation and instead prescribe FDA-approved first-line therapies (varenicline or combination NRT) supported by behavioral counseling.

Loading diagram... Algorithm for Longitudinal Tobacco Cessation Pharmacotherapy